EA199700260A1 - Готовая препаративная форма 2-метилтиенобензодиазепина для перорального введения и способ ее получения - Google Patents

Готовая препаративная форма 2-метилтиенобензодиазепина для перорального введения и способ ее получения

Info

Publication number
EA199700260A1
EA199700260A1 EA199700260A EA199700260A EA199700260A1 EA 199700260 A1 EA199700260 A1 EA 199700260A1 EA 199700260 A EA199700260 A EA 199700260A EA 199700260 A EA199700260 A EA 199700260A EA 199700260 A1 EA199700260 A1 EA 199700260A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oral administration
methyltienobenzodiazepina
ready
preparation
preparative form
Prior art date
Application number
EA199700260A
Other languages
English (en)
Other versions
EA000938B1 (ru
Inventor
Джордж Рэндалл Кочрэн
Томми Клиффорд Моррис
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23624847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199700260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199700260A1 publication Critical patent/EA199700260A1/ru
Publication of EA000938B1 publication Critical patent/EA000938B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Изобретение относится к фармацевтически совершенной твердой готовой препаративной форме для перорального введения оланзапина и к способу приготовления такой готовой препаративной формы.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199700260A 1995-03-24 1996-03-22 Готовая препаративная форма 2-метилтиенобензодиазепина для перорального введения и способ её получения EA000938B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41046595A 1995-03-24 1995-03-24
PCT/US1996/003918 WO1996029995A1 (en) 1995-03-24 1996-03-22 Oral 2-methyl-thieno-benzodiazepine formulation

Publications (2)

Publication Number Publication Date
EA199700260A1 true EA199700260A1 (ru) 1998-02-26
EA000938B1 EA000938B1 (ru) 2000-06-26

Family

ID=23624847

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700260A EA000938B1 (ru) 1995-03-24 1996-03-22 Готовая препаративная форма 2-метилтиенобензодиазепина для перорального введения и способ её получения

Country Status (46)

Country Link
US (4) US5919485A (ru)
EP (2) EP1093815B1 (ru)
JP (1) JPH11502848A (ru)
KR (1) KR100408172B1 (ru)
CN (1) CN1178662C (ru)
AP (1) AP679A (ru)
AR (2) AR001405A1 (ru)
AT (3) ATE284695T1 (ru)
AU (1) AU696601B2 (ru)
BG (1) BG62594B1 (ru)
BR (1) BR9607791A (ru)
CA (1) CA2216372C (ru)
CH (1) CH691217A5 (ru)
CO (1) CO4700474A1 (ru)
CR (1) CR5278A (ru)
CZ (1) CZ296007B6 (ru)
DE (3) DE69615887T2 (ru)
DK (3) DK1093815T3 (ru)
EA (1) EA000938B1 (ru)
EE (1) EE03551B1 (ru)
EG (1) EG24077A (ru)
ES (2) ES2232379T3 (ru)
FI (1) FI973749A (ru)
GB (1) GB2313783B (ru)
HU (1) HU225269B1 (ru)
IL (1) IL117611A (ru)
IS (1) IS1903B (ru)
LT (1) LT4350B (ru)
LU (1) LU90115B1 (ru)
LV (1) LV11983B (ru)
MY (1) MY113440A (ru)
NO (1) NO320388B1 (ru)
NZ (1) NZ306111A (ru)
OA (1) OA10511A (ru)
PE (1) PE44997A1 (ru)
PL (1) PL188316B1 (ru)
PT (2) PT1093815E (ru)
RO (1) RO118370B1 (ru)
SE (1) SE9703206L (ru)
SI (3) SI9620041A (ru)
SK (1) SK283745B6 (ru)
TR (1) TR199701018T1 (ru)
TW (1) TW426526B (ru)
UA (1) UA44766C2 (ru)
WO (1) WO1996029995A1 (ru)
ZA (1) ZA962338B (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
BR9713215A (pt) * 1996-09-24 2000-04-04 Lilly Co Eli Formulação de partìcula revestida
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
DK1246827T3 (da) * 1999-12-28 2005-05-23 Cipla Ltd Nye polymorfe former af olanzapin
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030072729A1 (en) * 2001-05-15 2003-04-17 Christopher Szymczak Simethicone as weight gain enhancer
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2002255196A1 (en) * 2002-04-18 2003-10-27 Dr. Reddy's Laboratories Ltd. Rapidly dispersing solid oral compositions
ATE500258T1 (de) 2002-05-31 2011-03-15 Sandoz Ag Verfahren zur herstellung von olanzapin form i
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
US7029112B2 (en) * 2002-08-05 2006-04-18 Mars, Incorporated Ink-jet printing on surface modified edibles and products made
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
JP2007507548A (ja) * 2003-10-07 2007-03-29 アンドルックス ファーマスーティカルズ リミテッド ライアビリティ カンパニー 速崩壊型製剤
WO2005049090A2 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
BRPI0610780A2 (pt) * 2005-04-22 2016-09-06 Teva Pharma formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
CA2607949C (en) * 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
AR052472A1 (es) * 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
GB0522474D0 (en) 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
GB0522473D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
ATE465720T1 (de) * 2006-07-05 2010-05-15 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
DK2246051T3 (da) * 2008-01-31 2014-01-13 Kyorin Seiyaku Kk Fremgangsmåde til fremstilling af oralt sig hurtigt opløsende tablet omfattende imidafenacin som aktiv bestanddel
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US20110048048A1 (en) * 2009-03-25 2011-03-03 Thomas Gielda Personal Cooling System
AU2010229821A1 (en) * 2009-03-25 2011-11-17 Caitin, Inc. Supersonic cooling system
US8505322B2 (en) * 2009-03-25 2013-08-13 Pax Scientific, Inc. Battery cooling
US20110051549A1 (en) * 2009-07-25 2011-03-03 Kristian Debus Nucleation Ring for a Central Insert
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8365540B2 (en) * 2009-09-04 2013-02-05 Pax Scientific, Inc. System and method for heat transfer
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9517212B1 (en) * 2012-11-15 2016-12-13 Chandra Zaveri Medicated adhesive pad arrangement
CN103919782B (zh) * 2013-01-15 2016-12-28 天津药物研究院有限公司 一种含有奥氮平的药物组合物及其制备方法
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
KR20240036128A (ko) * 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. 침전 방지 저분자 약물 제제
CN113143878A (zh) * 2021-03-19 2021-07-23 杭州新诺华医药有限公司 奥氮平组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172831A (en) * 1974-11-26 1979-10-30 Lilly Industries Limited Thieno-benzodiazepines
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
NZ247703A (en) * 1992-05-29 1995-07-26 Lilly Industries Ltd Thienobenzdiazepine derivatives and medicaments thereof
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
DK1093815T3 (da) 2005-04-25
HU225269B1 (en) 2006-08-28
US7229643B2 (en) 2007-06-12
ATE284695T1 (de) 2005-01-15
EP0733367A1 (en) 1996-09-25
IS4565A (is) 1997-09-22
IL117611A0 (en) 1996-07-23
DE69615887D1 (de) 2001-11-22
AR001405A1 (es) 1997-10-22
CN1179102A (zh) 1998-04-15
PL322579A1 (en) 1998-02-02
SK128297A3 (en) 1998-03-04
CA2216372C (en) 2007-11-20
SE9703206D0 (sv) 1997-09-05
DE69634053D1 (de) 2005-01-20
HUP9800410A3 (en) 2000-01-28
PL188316B1 (pl) 2005-01-31
CO4700474A1 (es) 1998-12-29
JPH11502848A (ja) 1999-03-09
BR9607791A (pt) 1998-07-07
AT405606B (de) 1999-10-25
NZ306111A (en) 1999-02-25
MX9707186A (es) 1997-11-29
AP9701064A0 (en) 1997-10-31
EE9700328A (et) 1998-06-15
AU5428096A (en) 1996-10-16
CN1178662C (zh) 2004-12-08
CZ300197A3 (en) 1997-12-17
TW426526B (en) 2001-03-21
TR199701018T1 (xx) 1998-01-21
GB2313783B (en) 1998-11-18
CA2216372A1 (en) 1996-10-03
FI973749A0 (fi) 1997-09-22
SI0733367T1 (en) 2002-06-30
IS1903B (is) 2003-11-20
RO118370B1 (ro) 2003-05-30
KR19980703189A (ko) 1998-10-15
ZA962338B (en) 1997-09-22
LV11983A (lv) 1998-03-20
LV11983B (en) 1998-07-20
GB9719817D0 (en) 1997-11-19
SI1093815T1 (en) 2005-06-30
UA44766C2 (uk) 2002-03-15
KR100408172B1 (ko) 2004-02-18
SK283745B6 (sk) 2003-12-02
BG62594B1 (bg) 2000-03-31
NO974363L (no) 1997-11-17
AP679A (en) 1998-09-28
CH691217A5 (de) 2001-05-31
WO1996029995A1 (en) 1996-10-03
IL117611A (en) 2002-05-23
US20010018071A1 (en) 2001-08-30
US6780433B2 (en) 2004-08-24
DE69634053T2 (de) 2005-12-22
CZ296007B6 (cs) 2005-12-14
PT1093815E (pt) 2005-03-31
PE44997A1 (es) 1997-10-23
FI973749A (fi) 1997-09-22
US20050085462A1 (en) 2005-04-21
MY113440A (en) 2002-02-28
EA000938B1 (ru) 2000-06-26
NO974363D0 (no) 1997-09-22
DK109097A (da) 1997-11-12
EP1093815B1 (en) 2004-12-15
GB2313783A (en) 1997-12-10
EP1093815A1 (en) 2001-04-25
HUP9800410A2 (hu) 1998-07-28
SI9620041A (sl) 1998-06-30
US6190698B1 (en) 2001-02-20
LT4350B (lt) 1998-05-25
CR5278A (es) 1996-07-04
LU90115B1 (fr) 1997-09-10
ES2164837T3 (es) 2002-03-01
ES2232379T3 (es) 2005-06-01
DK173323B1 (da) 2000-07-24
PT733367E (pt) 2002-03-28
DE19681287T1 (de) 1998-03-19
AU696601B2 (en) 1998-09-17
NO320388B1 (no) 2005-11-28
ATA902296A (de) 1999-02-15
DK0733367T3 (da) 2001-11-26
EP0733367B1 (en) 2001-10-17
EE03551B1 (et) 2001-12-17
EG24077A (en) 2008-05-11
DE69615887T2 (de) 2002-04-11
SE9703206L (sv) 1997-09-05
BG101901A (en) 1998-10-30
ATE206924T1 (de) 2001-11-15
LT97149A (en) 1998-01-26
US5919485A (en) 1999-07-06
AR002720A1 (es) 1998-04-29
OA10511A (en) 2002-04-24

Similar Documents

Publication Publication Date Title
EA199700260A1 (ru) Готовая препаративная форма 2-метилтиенобензодиазепина для перорального введения и способ ее получения
EA199900331A1 (ru) Препарат из покрытых частиц
FI972945A (fi) Antigeenien antamiseen soveltuvia koostumuksia
NO174239C (no) Fremgangsmåte for fremstilling av et oralt, farmasöytisk preparat
EP0337256A3 (de) Verfahren zur Herstellung pharmazeutischer Mischungen
BG97198A (bg) Диалкокси-пиридинил-бензимидазолови производни, метод за получаването им и тяхното фармацевтично приложение
IT1201087B (it) Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
LU90951I2 (fr) Eurifel rcp felv et ses dérivés pharmaceutiquement acceptables
BR9709267A (pt) Preparação de anticorpo monoclonal para administração a um humano formulação farmacêutica uso de uma preparação de anticorpo monoclonal e processo para a fabricação de uma preparação de anticorpo monoclonal
NO821645L (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive benzoazepinderivater
NO975931D0 (no) Blanding for administrering av medikament
ES518692A0 (es) Metodo de preparacion de derivados farmaceuticamente activosaminoalcoil heterociclicos.
IS1667B (is) Hliðstæð aðferð við framleiðslu á meðferðarvirkumbis-aza-bísýklískum efnasamböndum
FI92603B (fi) Mikrobinen menetelmä syklosporiinien valmistamiseksi
FI930150A (fi) Menetelmä terapeuttisesti aktiivisten indolijohdannaisten valmistamiseksi
NO157503C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive azepinderivater.
ES2012339B3 (es) Preparacion oral de ajo y procedimiento para su fabricacion
DZ1468A1 (fr) Composés nouveaux.
FI901605A0 (fi) Tieno-triatsolo-diatsepiinijohdosten valmistusmenetelmä
NO991733D0 (no) FremgangsmÕte for fremstilling av et IgM-preparat for intraven°s administrering
FI97951B (fi) Menetelmä kiinteiden oraalisesti käytettävien ifosfamidivalmisteiden valmistamiseksi
NO880922D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive benzodioksolderivater.
FI974002A (fi) Menetelmä ranitidiinihydrokloridi 1 muodon valmistamiseksi
NO178375C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive NMDA-antagonister
NO980384D0 (no) Fremgangsmåte for fremstilling av fastdoseformer av svært lav-dose legemidler

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU